Angiogenesis and anti-angiogenesis in neuroblastoma

D. Ribatti, A. Vacca, B. Nico, G. De Falco, P. Giuseppe Montaldo, M. Ponzoni

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Angiogenesis is a biological process by which new capillaries are formed from pre-existing vessels. It occurs in physiological and pathological conditions, such as tumours, where a specific critical turning point is the transition from the avascular to the vascular phase. Tumour angiogenesis depends mainly on the release by neoplastic cells of growth factors specific for endothelial cells that able to stimulate the growth of the host's blood vessels. This review summarises the literature concerning the relationship between angiogenesis and progression in human neuroblastoma, the most common extracranial solid tumour of infancy and childhood. It is becoming increasingly evident that agents which interfere with blood vessel formation also block tumour progression. Accordingly, anti-angiogenic tumour therapy has gained much interest in preclinical and clinical assessments. The recent applications of anti-angiogenic agents which interfere or block neuroblastoma progression are reviewed.

Original languageEnglish
Pages (from-to)750-757
Number of pages8
JournalEuropean Journal of Cancer
Volume38
Issue number6
DOIs
Publication statusPublished - 2002

Fingerprint

Neuroblastoma
Blood Vessels
Neoplasms
Biological Phenomena
Intercellular Signaling Peptides and Proteins
Endothelial Cells
Growth
Therapeutics

Keywords

  • Angiogenesis
  • Angiostatic molecules
  • Retinoic acid
  • Tumour progression

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Angiogenesis and anti-angiogenesis in neuroblastoma. / Ribatti, D.; Vacca, A.; Nico, B.; De Falco, G.; Giuseppe Montaldo, P.; Ponzoni, M.

In: European Journal of Cancer, Vol. 38, No. 6, 2002, p. 750-757.

Research output: Contribution to journalArticle

Ribatti, D. ; Vacca, A. ; Nico, B. ; De Falco, G. ; Giuseppe Montaldo, P. ; Ponzoni, M. / Angiogenesis and anti-angiogenesis in neuroblastoma. In: European Journal of Cancer. 2002 ; Vol. 38, No. 6. pp. 750-757.
@article{8d424ccf6e2c480e93115499ae040b30,
title = "Angiogenesis and anti-angiogenesis in neuroblastoma",
abstract = "Angiogenesis is a biological process by which new capillaries are formed from pre-existing vessels. It occurs in physiological and pathological conditions, such as tumours, where a specific critical turning point is the transition from the avascular to the vascular phase. Tumour angiogenesis depends mainly on the release by neoplastic cells of growth factors specific for endothelial cells that able to stimulate the growth of the host's blood vessels. This review summarises the literature concerning the relationship between angiogenesis and progression in human neuroblastoma, the most common extracranial solid tumour of infancy and childhood. It is becoming increasingly evident that agents which interfere with blood vessel formation also block tumour progression. Accordingly, anti-angiogenic tumour therapy has gained much interest in preclinical and clinical assessments. The recent applications of anti-angiogenic agents which interfere or block neuroblastoma progression are reviewed.",
keywords = "Angiogenesis, Angiostatic molecules, Retinoic acid, Tumour progression",
author = "D. Ribatti and A. Vacca and B. Nico and {De Falco}, G. and {Giuseppe Montaldo}, P. and M. Ponzoni",
year = "2002",
doi = "10.1016/S0959-8049(01)00337-9",
language = "English",
volume = "38",
pages = "750--757",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",
number = "6",

}

TY - JOUR

T1 - Angiogenesis and anti-angiogenesis in neuroblastoma

AU - Ribatti, D.

AU - Vacca, A.

AU - Nico, B.

AU - De Falco, G.

AU - Giuseppe Montaldo, P.

AU - Ponzoni, M.

PY - 2002

Y1 - 2002

N2 - Angiogenesis is a biological process by which new capillaries are formed from pre-existing vessels. It occurs in physiological and pathological conditions, such as tumours, where a specific critical turning point is the transition from the avascular to the vascular phase. Tumour angiogenesis depends mainly on the release by neoplastic cells of growth factors specific for endothelial cells that able to stimulate the growth of the host's blood vessels. This review summarises the literature concerning the relationship between angiogenesis and progression in human neuroblastoma, the most common extracranial solid tumour of infancy and childhood. It is becoming increasingly evident that agents which interfere with blood vessel formation also block tumour progression. Accordingly, anti-angiogenic tumour therapy has gained much interest in preclinical and clinical assessments. The recent applications of anti-angiogenic agents which interfere or block neuroblastoma progression are reviewed.

AB - Angiogenesis is a biological process by which new capillaries are formed from pre-existing vessels. It occurs in physiological and pathological conditions, such as tumours, where a specific critical turning point is the transition from the avascular to the vascular phase. Tumour angiogenesis depends mainly on the release by neoplastic cells of growth factors specific for endothelial cells that able to stimulate the growth of the host's blood vessels. This review summarises the literature concerning the relationship between angiogenesis and progression in human neuroblastoma, the most common extracranial solid tumour of infancy and childhood. It is becoming increasingly evident that agents which interfere with blood vessel formation also block tumour progression. Accordingly, anti-angiogenic tumour therapy has gained much interest in preclinical and clinical assessments. The recent applications of anti-angiogenic agents which interfere or block neuroblastoma progression are reviewed.

KW - Angiogenesis

KW - Angiostatic molecules

KW - Retinoic acid

KW - Tumour progression

UR - http://www.scopus.com/inward/record.url?scp=0036211599&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036211599&partnerID=8YFLogxK

U2 - 10.1016/S0959-8049(01)00337-9

DO - 10.1016/S0959-8049(01)00337-9

M3 - Article

C2 - 11937307

AN - SCOPUS:0036211599

VL - 38

SP - 750

EP - 757

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 6

ER -